Last Updated on September 1, 2021 by The Health Master
Dr Reddy’s Laboratories and Zydus Pharma are recalling bottles of a product each, in the US market, for different reasons, according to the latest report of the US health regulator.
Dr Reddy’s Laboratories is recalling 37,560 bottles of Tizanidine HCl tablets, USP 4 mg, the latest enforcement report by the US Food and Drug Administration (USFDA) said.
The tablets are manufactured by Dr Reddy’s Laboratories at its Srikakulam facility, it added.
The product is used to treat the symptoms of muscle stiffness associated with conditions such as cerebral palsy or other neurological disorders.
The reason for the recall is “Failed Tablet/Capsule Specification: Some tablets are shaved,” the report said. The voluntary ongoing nationwide within the United States recall is a class II recall, it added.
As per the USFDA’s report, Zydus Pharmaceuticals (USA) Inc, is recalling 2,880 bottles of Carvedilol tablets, USP 25 mg in the US due to, “presence of foreign tablets/capsules; report of two Paroxetine tablets were found in the bottle.”
Carvedilol tablets are used to treat high blood pressure and heart failure.
The voluntary ongoing nationwide in the US recall is a class II recall, the report by the US health regulator said.
The tablets have been manufactured by Cadila Healthcare, and are distributed by Zydus Pharmaceuticals (USA), it added.
As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Drug Recall: Metformin oral solution batch due to nitrosamine impurity
J&J recalls these Sunscreens after carcinogen found in some sprays
Viona Pharma recalls 21,240 bottles of this Diabetes drug
Dr Reddy’s recalls 2,980 bottles of Atorvastatin Calcium tablets
Sun Pharma recalls 50,868 bottles of diabetes drug in US
Lupin, Sun, Jubilant recall generic medicines in US
CDSCO issues procedure for regulation of 19 FDCs out of 294
DCGI approves 3 FDCs containing Cefixime & Cefadroxil as rational
Disposal of seized drugs: High Court seeks details of procedures
CAIT urges Govt to take action against e-Pharmacies
India: First commercial batch of COVAXIN released
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
